Related Experiment Videos
AAV-mediated gene therapy for hemophilia
Linda B Couto1, Glenn F Pierce
1Avigen Inc, 1301 Harbor Bay Parkway, Alameda, CA 94502, USA.
Current Opinion in Molecular Therapeutics
|November 7, 2003
Summary
Gene therapy for hemophilia shows promise, with adeno-associated virus vectors leading to sustained cures in animal models. Further research into delivery methods is crucial for successful human clinical application and a potential one-injection cure.
Area of Science:
- * Medical Genetics
- * Hematology
- * Gene Therapy
Background:
- * Hemophilia, a genetic bleeding disorder, results from defective coagulation Factor VIII or IX genes.
- * Gene therapy for hemophilia has been explored for two decades since gene cloning.
- * Previous therapeutic approaches have yielded mixed results in human trials.
Purpose of the Study:
- * To review the progress and challenges in gene therapy for hemophilia.
- * To highlight the potential of adeno-associated virus (AAV) vectors in treating hemophilia.
- * To emphasize the importance of delivery systems for future clinical success.
Main Methods:
- * Review of preclinical studies in hemophilic animal models (mice and dogs).
- * Analysis of preliminary human clinical trial data.
- * Focus on adeno-associated virus (AAV) vector-based gene delivery systems.
Main Results:
- * AAV vectors demonstrated robust and sustained cures in hemophilic mice and dogs.
- * Preliminary human trials with AAV vectors have shown intriguing results.
- * Animal model successes suggest potential for human therapeutic applications.
Conclusions:
- * Gene therapy, particularly using AAV vectors, holds significant promise for curing hemophilia.
- * Overcoming delivery challenges is critical for translating preclinical success to human patients.
- * Successful gene therapy could lead to a curative, single-injection treatment for hemophilia.